Chronic rhinosinusitis with nasal polyps

14 trials 2 recruiting MedDRA PT
14 Registered trials
2 Recruiting
9 Unique sponsors
9 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
R Respiratory (ATC R) 4
D Dermatology (ATC D) 3
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody 3 substances
Monoclonal antibody (immune, humanized) 2 substances
Corticosteroid 1 substance
Phase III: 5 Phase II: 3 Phase IV: 4 Phase I: 1 Phase I (First in Human): 1

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

5 trials
  • AstraZeneca AB Commercial
    BENRALIZUMAB; MOMETASONE FUROATE
    2023-507987-38-00 5 countries 2021 n=79
    Ended
  • AstraZeneca AB Commercial
    TEZEPELUMAB
    2024-513862-20-00 7 countries 2025 n=356
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2024-516814-39-00 10 countries 2025 n=131
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2024-516815-26-00 11 countries 2025 n=135
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2025-522983-33-00 15 countries n=146
    Pending

Phase II

3 trials
  • Sanofi-Aventis Recherche & Developpement Commercial
    LUNSEKIMIG
    2024-511261-11-00 3 countries 2025 n=77
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    LUNSEKIMIG
    2024-515912-27-00 3 countries 2025 n=40
    Ended
  • Upstream Bio Inc. Commercial
    HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST CRLF2
    2023-508231-31-00 4 countries 2024 n=45
    Ended

Phase IV

4 trials
  • Instituto De Investigacion Marques De Valdecilla Academic
    MEPOLIZUMAB
    2023-505426-34-01 1 country 2023 n=75
    Recruiting
  • Medical University Of Vienna Academic
    DUPILUMAB
    2023-509815-10-00 1 country 2024 n=80
    Ended
  • Rigshospitalet Academic
    DUPILUMAB; MEPOLIZUMAB; MOMETASONE FUROATE; PREDNISOLONE
    2022-502250-14-00 1 country 2023 n=220
    Ended
  • UZ Leuven Academic
    DUPILUMAB
    2023-504014-30-00 1 country 2023 n=44
    Ended

Phase I

1 trial
  • Bambusa Therapeutics Inc. Commercial
    IMP not specified
    2025-523142-28-00 1 country n=36
    Pending

Phase I (First in Human)

1 trial
  • Instytut Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Pan We Wroclawiu Academic
    IMP not specified
    2024-516220-34-00 1 country n=600
    Not authorised
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 5 Phase II, Phase III 0
AstraZeneca AB Commercial 2 Phase III 1
Bambusa Therapeutics Inc. Commercial 1 Phase I 0
Upstream Bio Inc. Commercial 1 Phase II 0
Instituto De Investigacion Marques De Valdecilla Academic 1 Phase IV 1
Medical University Of Vienna Academic 1 Phase IV 0
Rigshospitalet Academic 1 Phase IV 0
UZ Leuven Academic 1 Phase IV 0
Instytut Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Pan We Wroclawiu Academic 1 Phase I (First in Human) 0
New trials by year
2021
1
2023
3
2024
2
2025
5
← All indication landscapes